Gluformin Combi

Gluformin Combi is an oral antidiabetic medication that combines metformin hydrochloride and sitagliptin. The product is marketed in the European Union and is available by prescription only. It belongs to the biguanide and DPP‑4 inhibitor drug classes and is intended for the management of type 2 diabetes mellitus in adults.

Gluformin Combi is prescribed as part of a comprehensive diabetes care plan that includes diet and exercise. It is used when monotherapy does not achieve adequate glycemic control.

- Adjunct to diet and exercise for adults with type 2 diabetes mellitus. - Combination therapy when metformin alone is insufficient. - May be considered when a patient requires both insulin sensitisation and incretin‑based therapy. - Used to improve fasting and post‑prandial blood glucose levels. - Often selected for patients who prefer a single‑pill regimen.

Side effects of Gluformin Combi vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common: - Gastrointestinal upset such as nausea, diarrhoea, or abdominal discomfort. - Upper respiratory tract infection symptoms. - Headache. - Mild hypoglycaemia, especially when combined with other glucose‑lowering agents. - Dizziness.

Serious: - Lactic acidosis (rare, associated with metformin). - Severe hypersensitivity reactions, including skin rash or angioedema. - Pancreatitis. - Significant renal impairment. - Hepatic failure.

Before starting Gluformin Combi, certain health considerations should be reviewed to minimise risk.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Evaluate hepatic status, as liver disease may increase the risk of lactic acidosis. - Monitor for signs of heart failure; use cautiously in patients with unstable cardiac conditions. - Review pregnancy and lactation status; the safety profile is not fully established. - Consider age‑related dose adjustments for elderly patients. - Ensure regular monitoring of blood glucose and HbA1c levels.

Gluformin Combi can interact with several medication groups, affecting its efficacy or safety.

Avoid: - Iodinated contrast agents used in imaging studies (risk of renal dysfunction). - Strong CYP3A4 inhibitors that may increase sitagliptin concentrations. - Cimetidine, which can raise metformin plasma levels.

Use with caution: - Other antidiabetic agents that increase hypoglycaemia risk (e.g., sulfonylureas, insulin). - Diuretics that may affect renal clearance of metformin. - ACE inhibitors or ARBs, especially in patients with compromised kidney function. - Alcohol consumption, which can potentiate metformin‑related lactic acidosis.